Membrane CD22 defines circulating myeloma-related cells as mature or later B cells

Laboratory Investigation

Volumn 77, Issue 4, 1997, Pages 333-344

  Perfetti, Vittorio ^a   Vignarelli, Maurizio Colli ^a   Bellotti, Vittorio ^a   Glennie, Martin J ^b   Zorzoli, Irene ^a   Ubbiali, Paola ^a   Obici, Laura ^a   Massa, Margherita ^a   Ippoliti, Giovanbattista ^a   Ascari, Edoardo ^a   Merlini, Giampaolo ^a,c  

^a UNIVERSITY OF PAVIA   (Italy)

^b SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD22 ANTIGEN; CELL DNA;

ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE DIFFERENTIATION; CYTOTOXICITY TEST; DNA CONTENT; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; MYELOMA; PLASMA CELL; PRIORITY JOURNAL; PROLYMPHOCYTE;

AMYLOIDOSIS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIGENS, CD; ANTIGENS, CD22; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; B-LYMPHOCYTES; BONE MARROW CELLS; CELL ADHESION MOLECULES; CLONE CELLS; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; IMMUNOTOXINS; LECTINS; LYMPHOCYTES; MEMBRANE GLYCOPROTEINS; MULTIPLE MYELOMA; N-GLYCOSYL HYDROLASES; PLANT PROTEINS; PLASMA CELLS;

EID: 0030661881     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Bakkus MHC, Heirman C, Van Riet I, Van Camp B, and Thielemans K (1992). Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation. Blood 80:2326-2335.
2. Barlogie B, Alexanian R, Dixon D, Smith L, Smallwood L, and Delasalle K (1985). Prognostic significance of tumor cell DNA and RNA content in multiple myeloma. Blood 66:338-341.
3. Bast EJEG, Van Camp B, Reynaert P, Wiringa G, and Ballieux RE (1982). Idiotypic peripheral blood lymphocytes in monoclonal gammopathy. Clin Exp Immunol 47:677-682.
4. Bellotti V, Stoppini M, Perfetti V, Zorzoli I, Marinone G, Invernizzi R, Zambelli LM, Arbustini E, Grasso M, Ferri G, Ascari E, and Merlini G (1992). Use of anti-idiotypic monoclonal antibody in studying amyloidogenic light chains in cells, urine and fibrils: Pathophysiology and clinical implications. Scand J Immunol 36:607-615.
5. Berenson J, Wong R, Kim K, Brown N, and Lichtenstein A (1987). Evidence for peripheral blood B lymphocyte but not T lymphocyte involvement in multiple myeloma. Blood 70: 1550-1553.
6. Bergamaschi G, Perfetti V, Tonon L, Novella A, Lucotti C, Danova M, Glennie MJ, Merlini G, and Cazzola M (1996). Saporin, a ribosome-inactivating protein used to prepare immunotoxins, induces cell death via apoptosis. Br J Haematol 93:789-794.
7. + peripheral blood cells expressing CD38, CD56, and monotypic immunoglobulin light chain. Blood 85:436-447.
8. Bergui L, Schena M, Gaidano G, Riva M, and Caligaris-Cappio F (1989). Interleukin-3 and interleukin-6 synergistically promote the proliferation and differentiation of malignant plasma cell precursors in multiple myeloma. J Exp Med 170:613-618.
9. Billadeau D, Quam L, Thomas W, Kay N, Greipp P, Kyle R, Oken MM, and Van Ness B (1992). Detection and quantitation of malignant cells in the peripheral blood of multiple myeloma patients. Blood 80:1818-1824.
10. Bonardi MA, French RR, Amlot P, Gromo G, Modena D, and Glennie MJ (1993). Delivery of saporin to human B-cell lymphoma using bispecific antibody: Targeting via CD22 but not CD19, CD37, or immunoglobulin results in efficient killing. Cancer Res 53:3015-3021.
11. Caligaris-Cappio F, Bergui L, Gregoretti MG, Gaidano G, Gaboli M, Schena M, Zambonin Zallone A, and Marchisio PC (1991). Role of bone marrow stromal cells in the growth of human multiple myeloma. Blood 77:2688-2693.
12. Caligaris-Cappio F, Bergui L, Tesio L, Pizzolo G, Malavasi F, Chilosi M, Campana D, Van Camp B, and Janossy G (1985). Identification of malignant plasma cell precursors in the bone marrow of multiple myeloma. J Clin Invest 76:1245-1251.
13. Campana D, Janossy G, Bofill M, Trejdosiewicz LK, Ma D, Hoffbrand AV, Mason DY, Lebacq A, and Forster HK (1985). Human B cell development. I. Phenotypic differences of B lymphocytes in the bone marrow and peripheral lymphoid tissue. J Immunol 134:1524-1530.
14. Carmagnola AL, Boccadoro M, Massaia M, and Pileri A (1983). The idiotypic specificities of lymphocytes in human monoclonal gammopathies: Analysis with the fluorescence activated cell sorter. Clin Exp Immunol 51:173-177.
15. Cassel A, Leibovitz N, Hornstirn L, Quitt M, and Aghai E (1990). Evidence for the existence of circulating monoclonal B-lymphocytes in multiple myeloma patients. Exp Hematol 18:1171-1173.
16. Chen BJ and Epstein J (1996). Circulating clonal lymphocytes in myeloma constitute a minor subpopulation of B cells. Blood 87:1972-1976.
17. Dörken B, Moldenhauer G, Pezzutto A, Schwartz R, Feller A, Kiesel S, and Nadler LM (1986). HD39 (B3), a B lineage-restricted antigen whose cell surface expression is limited to resting and activated human B lymphocytes. J Immunol 136:4470-4479.
18. Engel P, Wagner N, Smith H, and Tedder TF (1993). Structure/function analysis of CD22: domains that mediate adhesion. In: Schlossman SF, Boumsell L, Gilks W, Harlan JM, Kishimoto T, Morimoto C, Ritz J, Shaw S, Silverstein R, Springer T, Tedder TF, and Todd RF, editors. Leukocyte typing V-white cell differentiation antigens. Oxford: Oxford University Press, 526-527.
19. Epstein J (1997). Myeloma stem cell phenotype: Implications for treatment. Semin Hematol 11:43-49.
20. 2 antibodies for delivering saporin to lymphoma in vitro and in vivo. Cancer Res 51:2353-2361.
21. French RR, Hamblin TJ, Bell AJ, Tutt AL, and Glennie MJ (1995). Treatment of B-cell lymphomas with combination of bispecific antibodies and saporin. Lancet 346:223-224.
22. Garcia-Sanz R, Orfao A, Gonzalez M, Moro MJ, Hernandez JM, Ortega F, Borrego D, Carnero M, Casanova F, Jimenez R, Portera JA, and San Miguel JF (1995). Prognostic implications of DNA aneuploidy in 156 untreated multiple myeloma patients. Br J Haematol 90:106-112.
23. 2 antibody containing thioether-linked Fab'γ fragments. J Immunol 139:2367-2375.
24. Goto H, Shimazaki C, Ashihara E, Ohkawa K, Oku N, Inaba T, Murukami S, Fujita N, and Nakagawa M (1992). Effects of interleukin-3 and interleukin-6 on peripheral blood cells from multiple myeloma patients and their clinical significance. Acta Haematol 88:129-135.
25. Hamburger A and Salmon SE (1977). Primary bioassay of human myeloma stem cells. J Clin Invest 60:846-954.
26. Harada Y, Kawano MM, Huang N, Mahmoud MS, Lisukov IA, Mihara K, Tsujimoto T, and Kuramoto A (1996). Identification of early plasma cells in peripheral blood and their clinical significance. Br J Haematol 92:184-191.
27. King MA and Nelson DS (1989). Tumor cell heterogeneity in multiple myeloma: Antigenic, morphologic, and functional studies of cells from blood and bone marrow. Blood 73: 1925-1935.
28. King MA and Wells JV (1981). Cell-bound immunoglobulin on peripheral blood mononuclear cells of patients with myeloma. Clin Exp Immunol 45:552-556.
29. Kubagawa H, Vogler H, Capra JD, Lawton ME, and Cooper MD (1979). Studies on the clonal origin of multiple myeloma. Use of individually specific (idiotype) antibodies to trace the oncogenic event to its earliest point of expression in B-cell differentiation. J Exp Med 150:792-807.
30. + monoclonal B-lineage cells in peripheral blood from myeloma patients as late stage B cells. Blood 78:711-719.
31. Law CL, Sidorenko SP, and Clark EA (1994). Regulation of lymphocyte activation by the cell-surface molecule CD22. Immunol Today 15:442-449.
32. Liu YJ, Johnson GD, Gordon J, and MacLennan ICM (1992). Germinal centers in T-cell-dependent antibody responses, Immunol Today 13:17-21.
33. MacGahon AJ, Martin SJ, Bissonnette RP, Mahboubi A, Shi Y, Mogil RJ, Nishioka WK, and Green DR (1995). The end of the (cell) line: Methods for the study of apoptosis in vitro. In: Schwartz ML and Osborne AB, editors. "Cell death" methods in cell biology, vol 46. San Diego: Academic Press, 153-185.
34. MacLennan ICM (1992). In which cells does neoplastic transformation occur in myelomatosis? Curr Top Microbiol Immunol 182:209-214.
35. Malavasi F, Funaro A, Alessio M, De Monte LB, Ausiello CM, Dianzani U, Lanza F, Magrini E, Momo M, and Roggero S (1992). CD38: A multilineage cell activation molecule with a split personality. Int J Clin Lab Res 22:73-113.
36. Mason DY, Stein H, Gerdes J, Pulford KAF, Ralfkiaer E, Falini B, Erber WN, Micklem K, and Gatter KC (1987). Value of monoclonal anti-CD22 (p135) antibodies for the detection of normal and neoplastic B lymphoid cells. Blood 69:836-840.
37. Mellstedt H, Hammarström S, and Holm G (1974). Monoclonal lymphocyte population in human plasma cell myeloma. Clin Exp Immunol 17:371-384.
38. Merlini G, Waldenström JG, and Jayakar S (1980). A new improved clinical staging system for multiple myeloma based on analysis of 123 treated patients. Blood 55:1011-1019.
39. Millar BC, Bell JBG, Lakhani A, Ayliffe MJ, Selby PJ, and McElwain TJ (1988). A simple method for culturing myeloma cells from human bone marrow aspirates and peripheral blood in vitro. Br J Haematol 69:197-203.
40. O'Keefe TL, Williams GT, Davies SL, and Neuberger MS (1996). Hyperresponsive B cells in CD22-deficient mice. Science 274:798-801.
41. Osmond DG (1993). The turnover of B-cell populations. Immunol Today 14:34-37.
42. Peaker CJG and Neuberger MS (1993). Association of CD22 with the B cell antigen receptor. Eur J Immunol 23:1358-1363.
43. Perfetti V, Bellotti V, Garini P, Zorzoli I, Rovati B, Marinone MG, Ippoliti G, and Merlini G (1994). AL amyloidosis: Characterization of amyloidogenic cells by anti-idiotypic monoclonal antibodies. Lab Invest 71:853-861.
44. Perfetti V, Borden P, Tao M-H, Morrison SL, and Kabat EA (1991). Specificity and variable region cDNA sequence of an isogeneic monoclonal antiidiotype to an anti-α(1->6) dextran. Mol Immunol 28:505-515.
45. Pilarski LM and Belch AJ (1994). Circulating monoclonal B cells expressing P glycoprotein may be a reservoir of multidrug-resistant disease in multiple myeloma. Blood 83: 724-736.
46. Pilarski LM, Mant MJ, and Reuther BA (1985). Pre-B cells in peripheral blood of multiple myeloma patients. Blood 64: 416-422.
47. Pileri A and Tarocco RP (1974). In vivo kinetic studies in human myeloma. Haematologica 59:10-24.
48. Ralph QM, Brisco MJ, Joshua DE, Brown R, Gibson J, and Morley A (1993). Advancement of multiple myeloma from diagnosis through plateau phase to progression does not involve a new B-cell clone: Evidence from the Ig heavy chain gene. Blood 82:202-206.
49. Sawamura M, Murakami H, Tamura J, Matsushima T, Sato S, Naruse T, and Tsuchiya J (1994). Tumor necrosis factor-α and interleukin-4 promote the differentiation of myeloma cell precursors in multiple myeloma. Br J Haematol 88:17-23.
50. Shimazaki C, Gotoh H, Okn N, Ashihara E, lnaba T, Murakami S, Ura Y, Nakagawa M, and Fujita N (1992). Novel type of clonally involved cytoplasmic immunoglobulin-negative cells in multiple myeloma: Flow cytometric study. Acta Haematol 88:86-91.
51. Terstappen LWMM, Johnsen S, Segers-Nolten IMJ, and Loken MR (1990). Identification and characterization of plasma cells in normal human bone marrow by high-resolution flow cytometry. Blood 76:1739-1747.
52. Thomas X, Xiao HQ, Chang R, and Epstein J (1992). Circulating B lymphocytes in multiple myeloma patients contain an autocrine IL-6 driven pre-myeloma cell population. Curr Top Microbiol Immunol 182:202-207.
53. Van Riet I, Heirman C, Lacor P, De Waele M, Thielemans K, and Van Camp B (1989). Detection of monoclonal B lymphocytes in bone marrow and peripheral blood of multiple myeloma patients by immunoglobulin gene rearrangement studies. Br J Haematol 73:289-295.
54. Vescio RA, Cao J, Hong CH, Lee JC, Wu CH, Der Danielian M, Wu V, Newman R, Lichtenstein AK, and Berenson JR (1995). Myeloma Ig heavy chain V region sequences reveal prior antigenic selection and marked somatic mutation but no intraclonal diversity. J lmmunol 155:2487-2497.
55. Vitetta ES, Thorpe PE, and Uhr JW (1993). Immunotoxins: Magic bullets or misguided missiles?. Immunol Today 14: 252-259.
56. Wearne AJ, Joshua DE, Brown RD, and Kronenberg H (1987). Multiple myeloma: The relationship between CALLA (CD10) positive lymphocytes in the peripheral blood and light chain isotype expression. Br J Haematol 67:39-44.
57. Witzig TE, Dhodapkar MV, Kyle RA, and Greipp PR (1993). Quantitation of circulating peripheral blood plasma cells and their relationship to disease activity in patients with multiple myeloma. Cancer 72:108-113.